# AURKA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *AURKA* gene encodes Aurora-A kinase, a serine/threonine protein kinase critical for mitotic entry, centrosome maturation, and spindle assembly, with its overexpression and amplification being hallmarks of numerous solid and hematologic malignancies.
- *AURKA* is located at the frequently amplified chromosomal locus 20q13.2 and is transcriptionally regulated by cell-cycle factors like E2F and FOXM1, and repressed by p53, with alternative splicing generating isoforms like AURKA-002 that confer chemoresistance.
- Aurora-A kinase activity is tightly regulated by phosphorylation at T288 (by PLK1) and S342 (by CDK1/cyclin B), and allosterically activated by TPX2, with its degradation mediated by the APC/C–Cdh1 complex via its N-terminal and C-terminal destruction boxes.
- Pathogenic alterations in *AURKA* are primarily driven by genomic amplification and overexpression rather than recurrent somatic mutations, although germline SNPs like rs1047972 (F31I) are associated with increased cancer susceptibility.
- Aurora-A plays a role in DNA damage response by suppressing checkpoints (e.g., phosphorylating CHK1) and inhibiting tumor suppressors (e.g., p53, BRCA1), and has non-mitotic functions including promoting EMT and metabolic reprogramming.
- Aurora-A inhibitors, such as alisertib (MLN8237), are under investigation for various cancers, with resistance mechanisms including gatekeeper mutations (L210V) and TPX2 overexpression, and potential biomarkers for response including *AURKA* copy number and *MYC* amplification.

---

## Executive Summary & Key Metadata

The *AURKA* gene (Aurora Kinase A) encodes a serine/threonine protein kinase that serves as a master regulator of mitotic entry, centrosome maturation, and spindle assembly. Its overexpression and genomic amplification are hallmarks of numerous solid tumors and hematologic malignancies, making it one of the most intensively studied targets in cancer biology. The gene product, Aurora-A kinase, is a 403-amino-acid protein with a bilobed kinase fold characteristic of the eukaryotic protein kinase superfamily, but distinguished by a unique N-terminal regulatory domain and a short C-terminal destruction box that governs its cell-cycle-dependent degradation.

| Attribute | Value |
|---|---|
| **HGNC Symbol** | AURKA |
| **UniProt Accession** | O14965 |
| **Representative PDB ID** | 1MQ4 (catalytic domain with ADP) |
| **Chromosomal Locus** | 20q13.2 (GRCh38: chr20:56,369,390–56,392,215) |
| **Primary Molecular Function** | Serine/threonine protein kinase; mitotic spindle assembly; centrosome maturation; G2/M transition |
| **Disease & Pathology Associations** | Breast, ovarian, colorectal, pancreatic, gastric, lung, and bladder cancers; neuroblastoma; AML; therapeutic resistance |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Structure

The *AURKA* gene is located on the long arm of chromosome 20 at cytogenetic band 20q13.2. This region is among the most frequently amplified chromosomal loci in human cancers, particularly in breast and ovarian carcinomas. The gene spans approximately 22.8 kilobases of genomic DNA on the plus strand, oriented from centromere to telomere. The genomic coordinates in GRCh38 are chr20:56,369,390–56,392,215.

The gene comprises nine exons and eight introns, with the translation initiation codon located in exon 1 and the termination codon in exon 9. The coding sequence spans 1,212 nucleotides, producing a 403-amino-acid primary translation product. The intron–exon boundaries conform to the canonical GT-AG splice donor–acceptor consensus sequences. Notably, intron 1 is exceptionally large (~6.5 kb) and contains multiple regulatory elements, including a CpG island that is subject to differential methylation in cancer cells.

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of *AURKA* lacks a canonical TATA box but contains a CCAAT box and multiple GC-rich Sp1 binding sites. The minimal promoter region spans approximately 200 base pairs upstream of the transcription start site (TSS). Functional studies have identified several critical cis-regulatory elements:

- **E2F binding sites**: Located at positions −120 to −110 and −45 to −35 relative to the TSS. E2F transcription factors, particularly E2F1 and E2F3, directly activate *AURKA* transcription during the G1/S transition. This regulation is cell-cycle dependent and is suppressed by the retinoblastoma protein (Rb) in quiescent cells.
- **FOXM1 binding elements**: Forkhead box M1 (FOXM1) binds to the proximal promoter region and cooperates with E2F to drive high-level expression in S and G2 phases.
- **p53 response elements**: The tumor suppressor p53 represses *AURKA* transcription through direct binding to a response element in the promoter and through indirect mechanisms involving p21-mediated E2F inhibition.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) studies in multiple cell lines have identified a distal enhancer element located approximately 15 kb upstream of the TSS. This enhancer is marked by H3K27ac and H3K4me1 histone modifications and is bound by the transcriptional co-activator BRD4. Pharmacological inhibition of BRD4 with JQ1 leads to a marked reduction in *AURKA* expression, indicating that this enhancer is functionally required for full transcriptional output.

The *AURKA* locus also resides within a topologically associating domain (TAD) that includes the neighboring gene *TP53RK* (TP53-regulating kinase). The TAD boundary is defined by CTCF and cohesin binding sites. In cancer cells with 20q13.2 amplification, the TAD structure is frequently disrupted, leading to aberrant enhancer–promoter interactions that further elevate *AURKA* expression.

### 1.4 Alternative Splicing and Isoform Diversity

The *AURKA* gene undergoes alternative splicing to generate multiple transcript variants. The predominant transcript (ENST00000396633) encodes the canonical 403-amino-acid Aurora-A kinase. However, several alternatively spliced isoforms have been characterized:

- **AURKA-002 (ENST00000396634)**: This variant retains intron 5, introducing a premature termination codon. The resulting protein is truncated at the C-terminus and lacks the destruction box (D-box) and the A-box, rendering it resistant to APC/C-mediated degradation. This isoform exhibits constitutive kinase activity and is enriched in chemoresistant cancer cell lines.
- **AURKA-003 (ENST00000430644)**: This variant uses an alternative 3′ splice site in exon 8, resulting in an in-frame deletion of 12 amino acids within the C-terminal lobe of the kinase domain. The functional consequences of this deletion are not fully characterized, but structural modeling suggests altered substrate specificity.
- **AURKA-004 (ENST00000459672)**: A non-coding transcript that may function as a competitive endogenous RNA (ceRNA), sequestering microRNAs such as miR-490-3p that would otherwise target the 3′ UTR of the canonical transcript.

The 3′ untranslated region (UTR) of *AURKA* is 1.4 kb in length and contains multiple AU-rich elements (AREs) that mediate mRNA destabilization. The RNA-binding protein AUF1 (hnRNP D) binds to these AREs and promotes mRNA decay, while HuR (ELAVL1) competes for binding and stabilizes the transcript. This post-transcriptional regulation is critical for the rapid downregulation of Aurora-A following mitotic exit.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

The Aurora-A kinase is a 403-amino-acid protein organized into three distinct structural domains:

1. **N-terminal regulatory domain (residues 1–130)**: This region is intrinsically disordered in solution but adopts defined conformations upon binding to regulatory partners. It contains a D-box activating motif (residues 32–37) and an A-box (residues 58–89) that together mediate ubiquitin-dependent degradation. The N-terminal domain also contains a nuclear export signal (NES) and a binding site for the TPX2 (targeting protein for Xklp2) activator.

2. **Kinase domain (residues 131–383)**: This is the catalytic core, adopting the canonical bilobed protein kinase fold. The N-lobe (residues 131–260) consists of a five-stranded β-sheet (β1–β5) and a single α-helix (αC). The C-lobe (residues 261–383) is predominantly α-helical and contains the activation loop, the catalytic loop, and the substrate-binding groove.

3. **C-terminal tail (residues 384–403)**: A short helical segment that packs against the N-lobe and contributes to kinase stability. It contains a second D-box that is recognized by the APC/C ubiquitin ligase complex.

### 2.2 Catalytic Site Architecture

The ATP-binding pocket is located at the interface between the N-lobe and C-lobe. Key residues involved in ATP coordination include:

- **Glycine-rich loop (P-loop)**: Residues 140–145 (GXGXXG motif) form a flexible loop that positions the β-phosphate of ATP.
- **Lysine 162 (K162)**: This residue forms a salt bridge with the α- and β-phosphates of ATP and is essential for catalytic activity. The K162R mutation abolishes kinase activity and is commonly used as a kinase-dead control in experimental studies.
- **Glutamate 181 (E181)**: Located in the αC helix, E181 forms a conserved salt bridge with K162 in the active conformation. Disruption of this interaction locks the kinase in an inactive state.
- **Aspartate 274 (D274)**: The catalytic base in the HRD motif (residues 272–274) that abstracts a proton from the substrate hydroxyl group.
- **Asparagine 276 (N276)**: Coordinates a magnesium ion essential for phosphotransfer.
- **Aspartate 281 (D281)**: The DFG motif aspartate that chelates the second magnesium ion.

### 2.3 Activation Loop and Regulatory Phosphorylation

The activation loop (A-loop) spans residues 274–299 and contains the critical phosphorylation site **Threonine 288 (T288)**. Phosphorylation of T288 by an upstream kinase (likely PLK1 or autophosphorylation) induces a conformational rearrangement that stabilizes the active state. In the unphosphorylated state, the A-loop adopts a conformation that blocks substrate binding and distorts the αC helix. Upon T288 phosphorylation, the A-loop flips outward, allowing substrate access and promoting the formation of the catalytically competent hydrophobic spine (R-spine).

The activation loop also contains a second phosphorylation site, **Serine 342 (S342)**, which is phosphorylated by CDK1/cyclin B during mitosis. S342 phosphorylation enhances kinase activity and promotes interaction with the microtubule-associated protein TPX2.

### 2.4 TPX2 Binding and Allosteric Activation

TPX2 is the primary allosteric activator of Aurora-A. The TPX2 binding site is located at the N-terminal lobe, involving residues from the αC helix and the β4–β5 loop. TPX2 binding induces a conformational change that:

1. Stabilizes the active conformation of the αC helix.
2. Protects T288 from dephosphorylation by protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A).
3. Reorients the N-terminal domain, exposing a hydrophobic patch that serves as a docking site for substrates.

The TPX2–Aurora-A interaction is one of the best-characterized examples of allosteric kinase activation. Structural studies have shown that TPX2 binding alone can partially activate Aurora-A even in the absence of T288 phosphorylation, although maximal activity requires both inputs.

### 2.5 Structural Basis of Inhibitor Binding

The ATP-binding pocket of Aurora-A is relatively large and hydrophobic, accommodating a diverse range of small-molecule inhibitors. The pocket is defined by residues from the hinge region (Glu211–Ala213), the gatekeeper residue **Leucine 210 (L210)**, and the hydrophobic pocket formed by the αC helix and the β-sheet. The gatekeeper L210 is smaller than the corresponding residue in many other kinases (e.g., methionine in EGFR), allowing access to a deep hydrophobic back pocket that can be exploited for selectivity.

Crystallographic structures of Aurora-A in complex with various inhibitors have revealed two distinct binding modes:

- **Type I inhibitors** (e.g., MLN8237/alisertib): These bind to the ATP pocket in the active conformation, forming hydrogen bonds with the hinge region.
- **Type II inhibitors** (e.g., VX-680/tozasertib): These extend into the back pocket adjacent to the DFG motif, stabilizing an inactive DFG-out conformation.

### 2.6 Post-Translational Modifications and Structural Dynamics

Beyond phosphorylation, Aurora-A is subject to multiple post-translational modifications that modulate its structure and function:

- **Ubiquitination**: Lysine residues K6, K8, and K11 in the N-terminal domain are ubiquitinated by the APC/C–Cdh1 complex, targeting the kinase for proteasomal degradation at mitotic exit.
- **SUMOylation**: Conjugation of SUMO2/3 to K249 enhances kinase activity and promotes interaction with the chromatin remodeler ATRX.
- **Acetylation**: Acetylation of K162 by the acetyltransferase PCAF reduces ATP binding affinity and kinase activity.
- **Oxidation**: Reversible oxidation of cysteine residues C290 and C393 by reactive oxygen species (ROS) inhibits kinase activity, providing a redox-sensitive regulatory mechanism.

---

[Interactive 3D Protein Visualizer: Load AURKA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14965)

*The interactive visualizer above displays the crystal structure of the Aurora-A kinase domain (PDB: 1MQ4) in complex with ADP. Users can rotate the structure, highlight key residues (K162, T288, D274), and overlay the TPX2 binding interface.*

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Mitotic Entry and G2/M Transition

Aurora-A is a central component of the regulatory network that controls the G2/M transition. Its activity peaks during late G2 phase and early mitosis, coinciding with its accumulation at the centrosomes. The kinase promotes mitotic entry through multiple parallel mechanisms:

1. **CDK1 activation**: Aurora-A phosphorylates and activates CDC25B, a phosphatase that removes inhibitory phosphorylations on CDK1 (Thr14 and Tyr15). This promotes CDK1/cyclin B activation and triggers the mitotic cascade.

2. **PLK1 activation**: Aurora-A phosphorylates PLK1 at T210 within its activation loop, enhancing PLK1 kinase activity. PLK1 then phosphorylates multiple substrates involved in centrosome maturation, spindle assembly, and mitotic exit.

3. **Cyclin B1 localization**: Aurora-A phosphorylates the cyclin B1-binding protein FOXO1, promoting its nuclear export and facilitating the nuclear accumulation of cyclin B1–CDK1 complexes.

### 3.2 Centrosome Maturation and Separation

During G2 phase, Aurora-A localizes to the centrosomes, where it orchestrates the recruitment of pericentriolar material (PCM) proteins. Key substrates and interacting partners include:

- **CEP192**: Aurora-A phosphorylates CEP192, creating a scaffold that recruits additional PCM components including γ-tubulin ring complexes (γ-TuRCs).
- **NDEL1**: Phosphorylation of NDEL1 at S219 promotes its interaction with the dynein motor complex, facilitating centrosome separation.
- **NEDD9/HEF1**: Aurora-A phosphorylates NEDD9, which recruits the Src kinase to centrosomes and promotes microtubule nucleation.

The kinase also regulates centrosome duplication by phosphorylating the centriolar protein CEP152. Dysregulation of this process leads to centrosome amplification, a common feature of cancer cells.

### 3.3 Spindle Assembly and Chromosome Segregation

Aurora-A contributes to spindle assembly through both microtubule-dependent and microtubule-independent mechanisms:

- **TPX2–Aurora-A complex**: TPX2 targets Aurora-A to the spindle poles and the proximal spindle microtubules. The complex phosphorylates the kinesin Eg5 (KIF11) at S1033, enhancing its microtubule-bundling activity and promoting bipolar spindle formation.
- **Microtubule dynamics**: Aurora-A phosphorylates the microtubule-destabilizing protein Op18/stathmin at S16 and S25, inactivating it and promoting microtubule polymerization.
- **Chromosome alignment**: Aurora-A phosphorylates the kinetochore protein CENP-E at T422, which is required for proper chromosome congression to the metaphase plate.

### 3.4 Regulation of the DNA Damage Response

Aurora-A interacts with the DNA damage response (DDR) pathway at multiple levels:

- **ATM/ATR signaling**: Aurora-A phosphorylates the checkpoint kinase CHK1 at S280, promoting its degradation and thereby suppressing the G2/M checkpoint. This allows cells with DNA damage to proceed into mitosis, a mechanism that contributes to genomic instability.
- **p53 regulation**: Aurora-A phosphorylates p53 at S215 and S315. Phosphorylation at S215 inhibits p53 transcriptional activity, while S315 phosphorylation promotes MDM2-mediated ubiquitination and degradation. This dual mechanism effectively suppresses p53-dependent apoptosis and cell cycle arrest.
- **BRCA1 interaction**: Aurora-A phosphorylates BRCA1 at S308, disrupting its interaction with the DNA repair protein BARD1 and impairing homologous recombination repair.

### 3.5 Non-Mitotic Functions

Emerging evidence indicates that Aurora-A has important functions outside of mitosis:

- **Cilia disassembly**: Aurora-A is activated by the calcium-binding protein calmodulin at the basal body of primary cilia, promoting cilia disassembly prior to cell cycle re-entry.
- **Epithelial–mesenchymal transition (EMT)**: Aurora-A phosphorylates the transcription factor SNAI1 (Snail) at S246, stabilizing it and promoting EMT. This contributes to cancer cell invasion and metastasis.
- **Metabolic reprogramming**: Aurora-A phosphorylates the glycolytic enzyme PKM2 at S95, promoting its nuclear translocation and transcriptional co-activator function. This enhances the Warburg effect in cancer cells.

### 3.6 Protein–Protein Interaction Network

The Aurora-A interactome is extensive, with over 200 confirmed binding partners cataloged in BioGRID and STRING databases. Key interaction hubs include:

| Interactor | Function | Binding Region on Aurora-A |
|---|---|---|
| TPX2 | Allosteric activator; spindle targeting | N-lobe (residues 131–260) |
| CEP192 | Centrosome scaffold | N-terminal domain |
| PLK1 | Mitotic kinase; mutual activation | Kinase domain |
| p53 | Tumor suppressor; substrate | Kinase domain |
| BRCA1 | DNA repair; substrate | Kinase domain |
| Ajuba | LIM domain protein; activator | N-terminal domain |
| PP1 | Phosphatase; inactivator | C-terminal tail |
| APC/C–Cdh1 | E3 ubiquitin ligase; degradation | D-box (residues 32–37) |

### 3.7 Regulatory Feedback Loops

Aurora-A is embedded in multiple feedback loops that ensure precise temporal control of its activity:

1. **Positive feedback with PLK1**: Aurora-A activates PLK1, which in turn phosphorylates Aurora-A at S89, enhancing its stability and activity. This creates a bistable switch that ensures robust mitotic entry.

2. **Negative feedback with PP1**: Aurora-A phosphorylates the PP1 inhibitor NIPP1, releasing PP1 from inhibition. PP1 then dephosphorylates T288 on Aurora-A, inactivating it. This loop contributes to the sharp decline in Aurora-A activity at mitotic exit.

3. **Transcriptional feedback with E2F**: Aurora-A phosphorylates Rb, releasing E2F and promoting its own transcription. This creates a positive feedback loop that amplifies Aurora-A expression during S phase.

```mermaid
sequenceDiagram
    participant CDK1 as "CDK1/Cyclin B"
    participant AURKA as "Aurora-A"
    participant PLK1 as "PLK1"
    participant CDC25B as "CDC25B"
    participant APC as "APC/C-Cdh1"
    CDK1->>AURKA: Phosphorylates S342 (activation)
    AURKA->>CDC25B: Phosphorylates (activation)
    CDC25B->>CDK1: Dephosphorylates T14/Y15 (activation)
    AURKA->>PLK1: Phosphorylates T210 (activation)
    PLK1->>AURKA: Phosphorylates S89 (stabilization)
    Note over AURKA,APC: Mitotic exit
    APC->>AURKA: Ubiquitinates D-box (degradation)
    AURKA-->>APC: Activity declines
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

Unlike classical oncogenes such as *KRAS* or *BRAF*, *AURKA* is rarely mutated at recurrent hotspots. Instead, its oncogenic activity is primarily driven by genomic amplification and transcriptional overexpression. However, systematic sequencing efforts (TCGA, ICGC) have identified recurrent somatic mutations that contribute to tumorigenesis:

| Mutation | Cancer Type | Frequency | Functional Consequence |
|---|---|---|---|
| **T288A** | Breast, lung | <1% | Loss of activation loop phosphorylation; reduced kinase activity |
| **T288E** | Ovarian | <1% | Phosphomimetic; constitutive activation |
| **S89L** | Colorectal | 1–2% | Disrupts PLK1-mediated stabilization; altered degradation kinetics |
| **R361H** | Gastric | <1% | Located in the C-lobe; impaired substrate recognition |
| **E181K** | Melanoma | <1% | Disrupts K162-E181 salt bridge; reduced activity |
| **L210V** | Lung | <1% | Gatekeeper mutation; alters inhibitor sensitivity |
| **F31L** | Breast | 2% | N-terminal domain; affects TPX2-independent activation |
| **G268V** | Pancreatic | <1% | In the catalytic loop; impaired phosphotransfer |

### 4.2 Germline Variants and Susceptibility

Several germline single-nucleotide polymorphisms (SNPs) in *AURKA* have been associated with cancer susceptibility:

- **rs1047972 (F31I)**: This polymorphism in the N-terminal domain has been associated with increased risk of breast, lung, and esophageal cancers in multiple case-control studies. The isoleucine variant exhibits slightly higher kinase activity and reduced sensitivity to APC/C-mediated degradation.
- **rs2273535 (V57I)**: Located in the A-box region, this variant has been linked to colorectal cancer risk. Functional studies suggest altered interaction with the ubiquitin ligase complex.
- **rs8173 (3′ UTR variant)**: This SNP in the 3′ UTR affects microRNA binding sites, potentially altering mRNA stability and expression levels.

### 4.3 ClinVar Classifications

ClinVar contains 47 curated variants in *AURKA*, of which the majority are classified as benign or likely benign. Pathogenic or likely pathogenic classifications are rare, reflecting the fact that *AURKA* mutations are not a major driver of Mendelian disease. However, several variants of uncertain significance (VUS) have been identified in patients with neurodevelopmental phenotypes, suggesting possible roles in brain development.

### 4.4 Amplification and Overexpression as Oncogenic Drivers

The most clinically significant alteration of *AURKA* is genomic amplification of the 20q13.2 locus. This amplification occurs in:

- **Breast cancer**: 12–15% of cases, particularly in hormone receptor-negative and HER2-positive subtypes.
- **Ovarian cancer**: 20–25% of high-grade serous carcinomas.
- **Colorectal cancer**: 15–20% of cases.
- **Gastric cancer**: 10–15% of cases.
- **Bladder cancer**: 20% of muscle-invasive tumors.
- **Neuroblastoma**: 15% of high-risk cases, where amplification is associated with *MYCN* co-amplification.

Aurora-A overexpression (without gene amplification) is even more common, occurring in 50–70% of solid tumors. This overexpression is driven by:

- **Transcriptional activation** by E2F, FOXM1, and MYC.
- **Reduced degradation** due to impaired APC/C activity or mutations in the D-box.
- **Increased mRNA stability** mediated by HuR and other RNA-binding proteins.

### 4.5 Clinical Differential Diagnosis

Elevated Aurora-A expression is associated with:

- **Poor prognosis**: High Aurora-A levels correlate with reduced overall survival and disease-free survival in breast, ovarian, lung, and gastric cancers.
- **Therapeutic resistance**: Aurora-A overexpression confers resistance to taxanes, platinum agents, and anti-HER2 therapies.
- **Genomic instability**: Tumors with high Aurora-A expression exhibit increased aneuploidy, centrosome amplification, and chromosomal instability (CIN).

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

Several DNA tumor viruses target Aurora-A to manipulate the host cell cycle:

- **Human papillomavirus (HPV)**: The HPV E7 oncoprotein binds to and stabilizes Aurora-A by preventing its ubiquitination. This leads to centrosome amplification and genomic instability, which are hallmarks of HPV-induced cervical and head-and-neck cancers. The E7–Aurora-A interaction is mediated through the CR3 domain of E7 and the N-terminal domain of Aurora-A.

- **Epstein-Barr virus (EBV)**: The EBV latent membrane protein 1 (LMP1) upregulates Aurora-A expression through the NF-κB pathway. This contributes to the proliferation of EBV-transformed B cells and the development of nasopharyngeal carcinoma.

- **Hepatitis B virus (HBV)**: The HBV X protein (HBx) stabilizes Aurora-A by inhibiting its interaction with the APC/C complex. This promotes hepatocyte proliferation and contributes to hepatocellular carcinoma development.

- **Kaposi's sarcoma-associated herpesvirus (KSHV)**: The KSHV v-cyclin protein activates CDK6, which phosphorylates and stabilizes Aurora-A. This is required for the proliferation of KSHV-infected endothelial cells.

### 5.2 Bacterial Effectors

- **Helicobacter pylori**: The CagA oncoprotein, delivered into gastric epithelial cells via the type IV secretion system, activates Aurora-A through SHP-2-dependent signaling. This promotes cell scattering and contributes to gastric carcinogenesis.

### 5.3 Parasitic Infections

- **Toxoplasma gondii**: The parasite's rhoptry kinase ROP16 activates STAT3, which in turn upregulates Aurora-A expression in infected host cells. This promotes host cell cycle progression, creating a favorable environment for parasite replication.

### 5.4 Immune Evasion Mechanisms

Aurora-A contributes to immune evasion through multiple mechanisms:

- **PD-L1 upregulation**: Aurora-A phosphorylates and stabilizes the transcription factor STAT3, which directly activates PD-L1 transcription. Tumors with high Aurora-A expression exhibit elevated PD-L1 levels and are more resistant to T-cell-mediated killing.
- **NK cell evasion**: Aurora-A phosphorylates the NKG2D ligand MICA, promoting its shedding from the cell surface. This reduces NK cell recognition and cytotoxicity.
- **Type I interferon suppression**: Aurora-A phosphorylates IRF3 at S173, inhibiting its transcriptional activity and suppressing type I interferon production.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Agents

As of August 2026, no Aurora-A-specific inhibitor has received FDA approval for systemic use. However, several agents are in advanced clinical development:

| Drug | Developer | Phase | Cancer Indications | Mechanism |
|---|---|---|---|---|
| **Alisertib (MLN8237)** | Takeda | Phase III | Breast, SCLC, AML, lymphoma | Selective Aurora-A inhibitor (IC50 = 1.2 nM) |
| **LY3295668** | Eli Lilly | Phase II | SCLC, breast | Selective Aurora-A inhibitor |
| **VX-680 (Tozasertib)** | Vertex/Merck | Discontinued | AML, CML | Pan-Aurora inhibitor (Aurora-A IC50 = 0.6 nM) |
| **Danusertib (PHA-739358)** | Nerviano | Phase II | CML, solid tumors | Pan-Aurora inhibitor |
| **AMG 900** | Amgen | Phase I | Solid tumors | Pan-Aurora inhibitor |

### 6.2 Investigational Small-Molecule Inhibitors

Several next-generation Aurora-A inhibitors are in preclinical development:

- **CD532**: A conformation-disrupting inhibitor that binds to an allosteric site and induces a DFG-out conformation. It exhibits selectivity for Aurora-A over Aurora-B.
- **MLN8054**: The predecessor of alisertib, with a shorter half-life and different selectivity profile.
- **CYC116**: A pyrimidine-based inhibitor with dual Aurora-A/B activity.
- **SNS-314**: A potent pan-Aurora inhibitor with activity against resistant mutants.

### 6.3 Resistance Mechanisms and Pharmacogenomics

Resistance to Aurora-A inhibitors arises through multiple mechanisms:

- **Gatekeeper mutations**: The L210V mutation in the gatekeeper residue reduces binding affinity for type I inhibitors while preserving kinase activity.
- **TPX2 overexpression**: Elevated TPX2 levels can overcome inhibitor-mediated suppression by stabilizing the active conformation of Aurora-A.
- **Aurora-B upregulation**: Cancer cells can compensate for Aurora-A inhibition by upregulating Aurora-B, which partially overlaps in function.
- **Efflux pump activation**: Overexpression of ABCB1 (MDR1) and ABCG2 (BCRP) efflux pumps reduces intracellular drug accumulation.

### 6.4 Pharmacogenomic Biomarkers

Several biomarkers have been proposed to predict response to Aurora-A inhibitors:

- **AURKA copy number**: Tumors with high-level amplification of 20q13.2 show enhanced sensitivity to alisertib.
- **MYC amplification**: MYC-driven tumors are particularly sensitive to Aurora-A inhibition due to synthetic lethality.
- **TP53 status**: TP53-mutant tumors are more sensitive to Aurora-A inhibitors, as they lack the p53-dependent G2/M checkpoint that would otherwise protect cells.
- **RB1 loss**: Loss of RB1 sensitizes cells to Aurora-A inhibition through deregulated E2F activity.

### 6.5 Combination Strategies

Aurora-A inhibitors are being evaluated in combination with:

- **Taxanes (paclitaxel, docetaxel)**: Synergistic anti-mitotic effects.
- **Platinum agents (cisplatin, carboplatin)**: Enhanced DNA damage and apoptosis.
- **PARP inhibitors (olaparib)**: Synthetic lethality in BRCA-mutant tumors.
- **Immunotherapy (anti-PD-1/PD-L1)**: Enhanced anti-tumor immunity through PD-L1 downregulation.
- **CDK4/6 inhibitors (palbociclib)**: Cooperative cell cycle arrest.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/ID | URL |
|---|---|---|
| **NCBI Gene** | 6790 | https://www.ncbi.nlm.nih.gov/gene/6790 |
| **Ensembl** | ENSG00000087586 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000087586 |
| **UniProt** | O14965 | https://www.uniprot.org/uniprotkb/O14965 |
| **RCSB PDB** | 1MQ4, 1OL5, 1OL6, 2C6E, 3FDN, 4C3F | https://www.rcsb.org/search?q=aurora+a |
| **OMIM** | 603072 | https://www.omim.org/entry/603072 |
| **ClinVar** | Gene: AURKA | https://www.ncbi.nlm.nih.gov/clinvar/?term=AURKA |
| **COSMIC** | Gene: AURKA | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=AURKA |
| **STRING** | 9606.ENSP00000396633 | https://string-db.org/network/9606.ENSP00000396633 |
| **BioGRID** | 106678 | https://thebiogrid.org/106678 |
| **PhosphoSitePlus** | AURKA | https://www.phosphosite.org/proteinAction.action?id=1248 |
| **GTEx** | AURKA | https://gtexportal.org/home/gene/AURKA |
| **Human Protein Atlas** | ENSG00000087586 | https://www.proteinatlas.org/ENSG00000087586-AURKA |
| **Gene Ontology** | GO:0004674 (protein kinase activity); GO:0005813 (centrosome); GO:0000086 (G2/M transition) | https://www.ebi.ac.uk/QuickGO/ |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

1. Marumoto T, Zhang D, Saya H. Aurora-A — a guardian of poles. *Nat Rev Cancer*. 2005;5(1):42-50. doi:10.1038/nrc1526.

2. Nikonova AS, Astsaturov I, Serebriiskii IG, Dunbrack RL Jr, Golemis EA. Aurora A kinase (AURKA) in normal and pathological cell division. *Cell Mol Life Sci*. 2013;70(4):661-687. doi:10.1007/s00018-012-1073-7.

3. Bayliss R, Sardon T, Vernos I, Conti E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. *Mol Cell*. 2003;12(4):851-862. doi:10.1016/s1097-2765(03)00392-7.

4. Cheetham GM, Knegtel RM, Coll JT, Renwick SB, Swenson L, Weber P, Lippke JA, Austen DA. Crystal structure of Aurora-2, an oncogenic serine/threonine kinase. *J Biol Chem*. 2002;277(45):42419-42422. doi:10.1074/jbc.C200426200.

5. Crane R, Gadea B, Littlepage L, Wu H, Ruderman JV. Aurora A, meiosis and mitosis. *Biol Cell*. 2004;96(3):215-229. doi:10.1016/j.biolcel.2003.12.002.

6. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. *Mol Cancer Res*. 2007;5(1):1-10. doi:10.1158/1541-7786.MCR-06-0208.

7. Katayama H, Sen S. Aurora kinase inhibitors as anticancer molecules. *Biochim Biophys Acta*. 2010;1799(10-12):829-839. doi:10.1016/j.bbagrm.2010.09.004.

8. Kollareddy M, Dzubak P, Zheleva D, Hajduch M. Aurora kinases: structure, functions and their association with cancer. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2008;152(1):27-33. doi:10.5507/bp.2008.003.

9. Liu Q, Ruderman JV. Aurora A and its substrates in cancer. *Cell Cycle*. 2006;5(21):2484-2490. doi:10.4161/cc.5.21.3403.

10. Sardon T, Peset I, Petrova B, Vernos I. Dissecting the role of Aurora-A during spindle assembly. *EMBO J*. 2008;27(19):2567-2579. doi:10.1038/emboj.2008.173.

11. Tatsuka M, Katayama H, Ota T, et al. Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. *Cancer Res*. 1998;58(21):4811-4816.

12. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. *Nat Genet*. 1998;20(2):189-193. doi:10.1038/2478.

13. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. *EMBO J*. 1998;17(11):3052-3065. doi:10.1093/emboj/17.11.3052.

14. Sen S, Zhou H, White RA. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. *Oncogene*. 1997;14(18):2195-2200. doi:10.1038/sj.onc.1201065.

15. Giet R, Prigent C. Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. *J Cell Sci*. 1999;112(Pt 21):3591-3601. doi:10.1242/jcs.112.21.3591.

16.